The National Health Service is reportedly exploring the option of prescribing weight-loss injections to children aged 12 and over who are living with severe obesity. This potential development marks a significant shift in the approach to tackling childhood obesity in the UK, a public health challenge with long-term implications for individual health and the wider healthcare system.
Sources indicate that the injections, such as semaglutide (marketed as Wegovy), would be offered to young people with a Body Mass Index (BMI) exceeding 35, alongside at least one weight-related comorbidity. These comorbidities could include conditions like high blood pressure, type 2 diabetes, or sleep apnoea. The proposed treatment would not be a standalone solution but would form part of a holistic weight management programme, encompassing dietary advice, physical activity, and psychological support.
This move follows updated guidance from the National Institute for Health and Care Excellence (NICE) in 2022, which recommended semaglutide for adults with a BMI of 35 or more and at least one weight-related condition. While the adult recommendations are already in place, extending this to a younger demographic would require careful consideration of the specific needs and potential impacts on children and adolescents.
Childhood obesity remains a pressing issue across the UK. According to NHS Digital data for 2022/23, 22.7% of children in Reception (aged 4-5) were overweight or obese, with this figure rising to 36.6% for children in Year 6 (aged 10-11). Severe obesity rates stood at 2.9% for Reception children and 5.8% for Year 6 children. These statistics underscore the urgent need for effective interventions.
The drugs work by mimicking a hormone called GLP-1, which helps regulate appetite and feelings of fullness. While clinical trials in adolescents have shown promising results in reducing weight, the long-term effects and broader implications for young people's health and development will be a key area of focus for health authorities as this proposal progresses. Any decision would be made with patient safety and efficacy as paramount considerations.